A non-lacquer 10 % topical solution of efinaconazole, developed by Valeant Pharmaceuticals International, received its first global approval in Canada in October 2013 for the treatment of onychomycosis. The product is under regulatory review in the US and Japan. The mechanism of anti-fungal activity of efinaconazole, a small-molecule triazole compound, appears to be similar to that of other anti-fungal triazoles, namely ergosterol synthesis inhibition. In particular, it appears to inhibit 14α demethylase, an enzyme involved in the conversion of lanosterol to ergosterol, resulting in secondary degenerative changes. This article summarizes the milestones in the development of efinaconazole leading to this first approval for onychomycosis.
KeywordsTerbinafine Tinea Pedis Ciclopirox Mycological Cure Topical Solution
- 6.Valeant Pharmaceuticals International Inc. Valeant Pharmaceuticals announces approval of Jublia® for the treatment of onychomycosis in Canada [media release]. 3 Oct 2013. http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-Approval-Of-Jublia-For-The-Treatment-Of-Onychomycosis-In-Canada/default.aspx.
- 7.Valeant Pharmaceuticals International Inc. Valeant pharmaceuticals announces receipt of U.S. FDA complete response letter for efinaconazole [media release]. 28 May 2013. http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-Receipt-Of-US-FDA-Complete-Response-Letter-For-Efinaconazole.
- 8.Kaken Pharmaceutical Co. Ltd. R&D pipeline. 2013. http://www.kaken.co.jp/english/rd_pipeline.html. Accessed 22 Oct 2013.
- 9.Valeant Pharmaceuticals International Inc. Valeant pharmaceuticals provides efinconazole update [media release]. 2 May 2013. http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Provides-Efinconazole-Update/default.aspx.
- 10.Valeant Pharmaceuticals International Inc. Valeant pharmaceuticals announces award in Anacor dispute [media release]. 18 Oct 2013. http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-Award-In-Anacor-Dispute/default.aspx.
- 11.Valeant Pharmaceuticals Inc. Valeant Pharmaceuticals announces settlement agreement with Anacor [media release]. 28 Oct 2013. http://ir.valeant.com/investor-relations/news-releases/news-release-details/2013/Valeant-Pharmaceuticals-Announces-Settlement-Agreement-With-Anacor/default.aspx.
- 12.Kaken P. Kaken pharmaceutical to license its antifungal compound KP-103 to Dow Pharmaceutical Sciences [media release]. 11 May 2006. http://www.japancorp.net/article.asp?Art_ID=12471.
- 13.Valeant Pharmaceuticals International Inc. Valeant Pharmaceuticals completes acquisition of Dow Pharmaceutical Sciences Inc [media release]. 2 Jan 2009. http://ir.valeant.com/investor-relations/news-releases/news-release-details/2009/Valeant-Pharmaceuticals-Completes-Acquisition-of-Dow-Pharmaceutical-Sciences-Inc/default.aspx.
- 15.Bhatt V, Sarpotdar P, Pillai R, et al. Development of an optimal formulation for efinaconazole a novel antifungal agent for the treatment of onychomycosis by topical application [abstract no. P6541]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB104.Google Scholar
- 19.Sugiura K, Hosaka S, Sugimoto N, et al. Efinaconazole’s nail penetration and fungicidal activity may contribute to its therapeutic efficacy as a topical treatment for onychomycosis [abstract no. 1151]. J Invest Dermatol. 2013;133(Suppl 1):S195.Google Scholar
- 21.Glynn M, Nejishima H, Sanada H, et al. Efinaconazole 10 % solution: nonclinical safety supports topical use in onychomycosis [abstract no. P6552]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB105.Google Scholar
- 22.Jo W, Glynn M, Minowa K, et al. Efinaconazole: developmental and reproductive toxicity potential [abstract no. P712]. Int J Toxicol. 2013;32(1):82–3.Google Scholar
- 23.Jo Siu W, Mutter L, Aoyama A, et al. In vitro CYP inhibition and induction assessments of efinaconazole coupled with low clinical systemic exposure suggest low DDI potential in topical onychomycosis [abstract no. 1140]. J Invest Dermatol. 2013;133 Suppl 1:S193.Google Scholar